Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Interest Receivables Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Tenax Therapeutics (TENX) Long-Term Debt Issuances (2022)

Tenax Therapeutics' Long-Term Debt Issuances history spans 2 years, with the latest figure at $1.0 for Q1 2012.

On a quarterly basis, Long-Term Debt Issuances changed N/A to $1.0 in Q1 2012 year-over-year; TTM through Jan 2014 was $1.0, a N/A change, with the full-year FY2022 number at $624302.0, changed N/A from a year prior.
Long-Term Debt Issuances hit $1.0 in Q1 2012 for Tenax Therapeutics, up from -$1.0 in the prior quarter.
Over the last five years, Long-Term Debt Issuances for TENX hit a ceiling of $4.5 million in Q3 2011 and a floor of -$1.0 in Q4 2011.